Economic impact of adopting pemetrexed plus cisplatin for malignant pleural mesothelioma into Scottish clinical practice

被引：0
|
作者：
Chetty, M
Cordony, A
Davey, P
Karampela, K
Le Reun, C
Watt, M
机构：
[1] MTAG Pty Ltd, Chatswood, NSW, Australia
[2] Eli Lilly & Co, Basingstoke, Hants, England
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67239-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A33 / A33
页数：1
相关论文
共 50 条
  • [31] Use of forced vital capacity (FVC) measurement for the clinical management of malignant pleural mesothelioma (MPM): Observations from the pemetrexed plus cisplatin versus cisplatin study
    Pistolesi, M
    Symanowski, J
    Rusthoven, J
    Paoletti, P
    McAndrews, P
    Vogenizang, N
    LUNG CANCER, 2005, 49 : S227 - S227
  • [32] A Feasibility Study of Induction Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Postoperative Hemithoracic Radiation for Malignant Pleural Mesothelioma
    Yamanaka, Takeharu
    Tanaka, Fumihiro
    Hasegawa, Seiki
    Okada, Morihito
    Soejima, Toshinori
    Kamikonya, Norihiko
    Fukuoka, Kazuya
    Nakano, Takashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (03) : 186 - 188
  • [33] Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma
    Krug, Lee M.
    Pass, Harvey I.
    Rusch, Valerie W.
    Kindler, Hedy L.
    Sugarbaker, David J.
    rosenzweig, Kenneth E.
    Flores, Raja
    Friedberg, Joseph S.
    Pisters, Katherine
    Monberg, Matthew
    Obasaju, Coleman K.
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 3007 - 3013
  • [34] LUME-MeSO: Phase II/III Study of Nintedanib plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma
    Scagliotti, Giorgio V.
    Gaafar, Rabab
    Nowak, Anna
    Vogelzang, Nicholas J.
    Von Wangenheim, Ute
    Morsli, Nassim
    Velema, Derek
    Popat, Sanjay
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S216 - S216
  • [35] Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of malignant pleural mesothelioma (MPM)
    Rea, F.
    Favaretto, A. G.
    Marulli, G.
    Spaggiari, L.
    De Pas, T. M.
    Ceribelli, A.
    Paccagnella, A.
    Crivellari, G.
    Russo, F.
    Ceccarelli, M.
    Facciolo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Clinical practice guidelines for malignant pleural mesothelioma
    van Zandwijk, Nico
    JOURNAL OF THORACIC DISEASE, 2013, 5 (06) : 724 - 725
  • [37] Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial
    Zhan, Mei
    Zheng, Hanrui
    Xu, Ting
    Yang, Yu
    Li, Qiu
    LUNG CANCER, 2017, 110 : 1 - 6
  • [38] First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
    Fujimoto, Eriko
    Kijima, Takashi
    Kuribayashi, Kozo
    Negi, Yoshiki
    Kanemura, Shingo
    Mikami, Koji
    Doi, Hiroshi
    Kitajima, Kazuhiro
    Nakano, Takashi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (09) : 865 - 872
  • [39] Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
    Vogelzang, NJ
    Rusthoven, JJ
    Symanowski, J
    Denham, C
    Kaukel, E
    Ruffie, P
    Gatzemeier, U
    Boyer, M
    Emri, S
    Manegold, C
    Niyikiza, C
    Paoletti, P
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2636 - 2644
  • [40] First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
    Fujimoto, E.
    Kuribayashi, K.
    Kanemura, S.
    Negi, Y.
    Koda, Y.
    Mikami, K.
    Minami, T.
    Yokoi, T.
    Nakano, T.
    Kijima, T.
    ANNALS OF ONCOLOGY, 2017, 28
12345